Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$18.57 - $23.23 $230,268 - $288,052
-12,400 Reduced 56.11%
9,700 $189,000
Q2 2024

Aug 14, 2024

BUY
$17.53 - $22.98 $215,619 - $282,654
12,300 Added 125.51%
22,100 $455,000
Q1 2024

May 15, 2024

BUY
$13.42 - $23.53 $21,472 - $37,648
1,600 Added 19.51%
9,800 $209,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $15,918 - $30,198
-2,100 Reduced 20.39%
8,200 $117,000
Q3 2023

Nov 14, 2023

SELL
$8.44 - $11.86 $44,732 - $62,858
-5,300 Reduced 33.97%
10,300 $93,000
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $109,667 - $159,486
11,400 Added 271.43%
15,600 $165,000
Q1 2023

May 15, 2023

SELL
$10.71 - $14.6 $25,704 - $35,040
-2,400 Reduced 36.36%
4,200 $51,000
Q4 2022

Feb 14, 2023

SELL
$11.23 - $16.9 $713,105 - $1.07 Million
-63,500 Reduced 90.58%
6,600 $81,000
Q3 2022

Nov 14, 2022

BUY
$12.01 - $19.45 $10,809 - $17,505
900 Added 1.3%
70,100 $958,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.